Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5693549 | 1.00 | CASP1 (0.44) | CASP1RAB9AKMT2AATMMEN1 | |
| SCHEMBL14417347 | 1.00 | CASP1 (0.44) | CASP1RAB9AKMT2AATMMEN1 | |
| SCHEMBL13802834 | 0.88 | CYP1A2 (0.49) | RAB9AKMT2AMEN1LMNACYP2D6 | |
| SCHEMBL12861466 | 0.87 | KMT2A (0.48) | RAB9AKMT2AATMMEN1LMNA | |
| SCHEMBL12498544 | 0.86 | CASP1 (0.54) | CASP1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL8299927 | 0.86 | CASP1 (0.54) | CASP1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL29839087 | 0.86 | CASP1 (0.54) | CASP1RAB9AKMT2AMEN1LMNA | |
| SCHEMBL12524006 | 0.85 | CFD (0.52) | HTTCTSAMAPT | |
| SCHEMBL14662635 | 0.83 | ESR1 (0.46) | ATMCTSA | |
| SCHEMBL381854 | 0.82 | HTT (0.50) | HTTCTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683699-B1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI SA (FR) | 2015-06-24 | — | — | EP | disclosed |
| EP-2683705-B1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| EP-2683700-B1 | TETRA-SUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR THEIR PREPARATION, THEIR USAGE AS MEDICAMENT AND MEDICAMENT CONTAINING SAME AND ITS USE | SANOFI SA (FR) | 2015-02-18 | — | — | EP | disclosed |
| EP-2683700-A1 | TETRASUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF | SANOFI (FR) | 2014-01-15 | — | — | EP | disclosed |
| EP-2683699-A1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI (FR) | 2014-01-15 | — | — | EP | disclosed |
| EP-2683705-A1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI (FR) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012120054-A1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120056-A1 | TETRASUBSTITUTED OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, THEIR USE AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND THE USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120055-A1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
| US-20070225320-A1 | PROCESS FOR PREPARING CLOPIDOGREL | DR. REDDY'S LABORATORIES, INC. | 2007-09-27 | — | — | US | disclosed |
| EP-1638944-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000821-A1 | TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225320-A1 | PROCESS FOR PREPARING CLOPIDOGREL | PFKP, SELP, P2RY13 | CASP1 3089/4885RAB9A 1270/4885KMT2A 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.